<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37736756</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9.</ArticleTitle><Pagination><StartPage>5898</StartPage><MedlinePgn>5898</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5898</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-41603-0</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss, with additional pathophysiological involvement of non-neuronal cells such as microglia. The commonest ALS-associated genetic variant is a hexanucleotide repeat expansion (HRE) mutation in C9orf72. Here, we study its consequences for microglial function using human iPSC-derived microglia. By RNA-sequencing, we identify enrichment of pathways associated with immune cell activation and cyto-/chemokines in C9orf72 HRE mutant microglia versus healthy controls, most prominently after LPS priming. Specifically, LPS-primed C9orf72 HRE mutant microglia show consistently increased expression and release of matrix metalloproteinase-9 (MMP9). LPS-primed C9orf72 HRE mutant microglia are toxic to co-cultured healthy motor neurons, which is ameliorated by concomitant application of an MMP9 inhibitor. Finally, we identify release of dipeptidyl peptidase-4 (DPP4) as a marker for MMP9-dependent microglial dysregulation in co-culture. These results demonstrate cellular dysfunction of C9orf72 HRE mutant microglia, and a non-cell-autonomous role in driving C9orf72-ALS pathophysiology in motor neurons through MMP9 signaling.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vahsen</LastName><ForeName>Bj&#xf6;rn F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-5159-5070</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalluru</LastName><ForeName>Sumedha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Georgia R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrimond</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yinyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Medical Sciences (CAMS), CAMS Oxford Institute (COI), Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cramb</LastName><ForeName>Kaitlyn M L</ForeName><Initials>KML</Initials><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amein</LastName><ForeName>Benazir</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0004-1314-3518</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scaber</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0146-1821</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsikoudi</LastName><ForeName>Antigoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Neurodegeneration Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candalija</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcol&#xe9;</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5054-9016</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WCIN 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dafinca</LastName><ForeName>Ruxandra</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0776-6431</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6820-5534</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WCIN 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wade-Martins</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6691-580X</Identifier><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowley</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-0297-6675</Identifier><AffiliationInfo><Affiliation>James and Lillian Martin Centre for Stem Cell Research, Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK. sally.cowley@path.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Oxford Motor Neuron Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK. kevin.talbot@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK. kevin.talbot@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>203141/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N013468/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>102176/Z/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024962/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>5</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37736756</ArticleId><ArticleId IdType="pmc">PMC10517114</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-41603-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-41603-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Kankel MW, Su SC, Han SWS, Ofengeim D. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. Cell Death Differ. 2018;25:648&#x2013;662. doi: 10.1038/s41418-018-0060-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0060-4</ArticleId><ArticleId IdType="pmc">PMC5864209</ArticleId><ArticleId IdType="pubmed">29459769</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A, Patani R. Concise review: the cellular conspiracy of amyotrophic lateral sclerosis. Stem Cells. 2018;36:293&#x2013;303. doi: 10.1002/stem.2758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2758</ArticleId><ArticleId IdType="pubmed">29235200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahsen BF, et al. Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers. Nat. Rev. Neurol. 2021;17:333&#x2013;348. doi: 10.1038/s41582-021-00487-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00487-8</ArticleId><ArticleId IdType="pubmed">33927394</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 2017;35:441&#x2013;468. doi: 10.1146/annurev-immunol-051116-052358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-051116-052358</ArticleId><ArticleId IdType="pmc">PMC8167938</ArticleId><ArticleId IdType="pubmed">28226226</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007;8:57&#x2013;69. doi: 10.1038/nrn2038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2038</ArticleId><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Feneberg E, Scaber J, Thompson AG, Turner MR. Amyotrophic lateral sclerosis: the complex path to precision medicine. J. Neurol. 2018;265:2454&#x2013;2462. doi: 10.1007/s00415-018-8983-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8983-8</ArticleId><ArticleId IdType="pmc">PMC6182683</ArticleId><ArticleId IdType="pubmed">30054789</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e39216. doi: 10.1371/journal.pone.0039216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039216</ArticleId><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. 2012;123:395&#x2013;407. doi: 10.1007/s00401-011-0932-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0932-x</ArticleId><ArticleId IdType="pmc">PMC3595560</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329. doi: 10.1126/science.aaf1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585:96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, et al. C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron. 2021;109:2275&#x2013;2291.e2278. doi: 10.1016/j.neuron.2021.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.05.020</ArticleId><ArticleId IdType="pmc">PMC8298293</ArticleId><ArticleId IdType="pubmed">34133945</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wilgenburg B, Browne C, Vowles J, Cowley SA. Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS ONE. 2013;8:e71098. doi: 10.1371/journal.pone.0071098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071098</ArticleId><ArticleId IdType="pmc">PMC3741356</ArticleId><ArticleId IdType="pubmed">23951090</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W, et al. A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Rep. 2017;8:1727&#x2013;1742. doi: 10.1016/j.stemcr.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5470330</ArticleId><ArticleId IdType="pubmed">28591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahsen BF, et al. Human iPSC co-culture model to investigate the interaction between microglia and motor neurons. Sci. Rep. 2022;12:12606. doi: 10.1038/s41598-022-16896-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16896-8</ArticleId><ArticleId IdType="pmc">PMC9308778</ArticleId><ArticleId IdType="pubmed">35871163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ababneh NA, et al. Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. Hum. Mol. Genet. 2020;29:2200&#x2013;2217. doi: 10.1093/hmg/ddaa106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa106</ArticleId><ArticleId IdType="pmc">PMC7399532</ArticleId><ArticleId IdType="pubmed">32504093</ArticleId></ArticleIdList></Reference><Reference><Citation>York EM, LeDue JM, Bernier LP, MacVicar BA. 3DMorph automatic analysis of microglial morphology in three dimensions from ex vivo and in vivo imaging. eNeuro. 2018;5:ENEURO.0266-0218.2018. doi: 10.1523/ENEURO.0266-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0266-18.2018</ArticleId><ArticleId IdType="pmc">PMC6325541</ArticleId><ArticleId IdType="pubmed">30627639</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, et al. G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol. Med. 2018;10:22&#x2013;31. doi: 10.15252/emmm.201707850.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707850</ArticleId><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2013;1283.e1266. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A, et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron. 2014;81:333&#x2013;348. doi: 10.1016/j.neuron.2013.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.009</ArticleId><ArticleId IdType="pmc">PMC6015650</ArticleId><ArticleId IdType="pubmed">24462097</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, et al. Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiol. Dis. 2019;124:133&#x2013;140. doi: 10.1016/j.nbd.2018.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.11.013</ArticleId><ArticleId IdType="pmc">PMC7053168</ArticleId><ArticleId IdType="pubmed">30458231</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bartheld CS, Bahney J, Herculano-Houzel S. The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. J. Comp. Neurol. 2016;524:3865&#x2013;3895. doi: 10.1002/cne.24040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24040</ArticleId><ArticleId IdType="pmc">PMC5063692</ArticleId><ArticleId IdType="pubmed">27187682</ArticleId></ArticleIdList></Reference><Reference><Citation>Valverde A, et al. Dipeptidyl peptidase 4 contributes to Alzheimer&#x2019;s disease-like defects in a mouse model and is increased in sporadic Alzheimer&#x2019;s disease brains. J. Biol. Chem. 2021;297:100963. doi: 10.1016/j.jbc.2021.100963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100963</ArticleId><ArticleId IdType="pmc">PMC8334387</ArticleId><ArticleId IdType="pubmed">34265307</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 2014;588:3870&#x2013;3877. doi: 10.1016/j.febslet.2014.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.08.029</ArticleId><ArticleId IdType="pubmed">25217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzini I, et al. Moderate intrinsic phenotypic alterations in C9orf72 ALS/FTD iPSC-microglia despite the presence of C9orf72 pathological features. Front. Cell. Neurosci. 2023;17:1179796. doi: 10.3389/fncel.2023.1179796.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2023.1179796</ArticleId><ArticleId IdType="pmc">PMC10279871</ArticleId><ArticleId IdType="pubmed">37346371</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee P, et al. Cell-autonomous immune dysfunction driven by disrupted autophagy in C9orf72-ALS iPSC-derived microglia contributes to neurodegeneration. Sci. Adv. 2023;9:eabq0651. doi: 10.1126/sciadv.abq0651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abq0651</ArticleId><ArticleId IdType="pmc">PMC10121169</ArticleId><ArticleId IdType="pubmed">37083530</ArticleId></ArticleIdList></Reference><Reference><Citation>Laflamme C, et al. Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. elife. 2019;8:e48363. doi: 10.7554/eLife.48363.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.48363</ArticleId><ArticleId IdType="pmc">PMC6794092</ArticleId><ArticleId IdType="pubmed">31612854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 2018;24:313&#x2013;325. doi: 10.1038/nm.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers J, Tharkeshwar AK, Van Damme P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy. 2021;17:3306&#x2013;3322. doi: 10.1080/15548627.2021.1872189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2021.1872189</ArticleId><ArticleId IdType="pmc">PMC8632097</ArticleId><ArticleId IdType="pubmed">33632058</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, Barbagallo P, Talbot K. The role of mitochondrial dysfunction and ER stress in TDP-43 and C9ORF72 ALS. Front. Cell. Neurosci. 2021;15:653688. doi: 10.3389/fncel.2021.653688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.653688</ArticleId><ArticleId IdType="pmc">PMC8047135</ArticleId><ArticleId IdType="pubmed">33867942</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard SM, Razak K, Ethell IM. A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front. Cell. Neurosci. 2015;9:280. doi: 10.3389/fncel.2015.00280.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00280</ArticleId><ArticleId IdType="pmc">PMC4518323</ArticleId><ArticleId IdType="pubmed">26283917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J. Neurochem. 2016;139:91&#x2013;114. doi: 10.1111/jnc.13415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13415</ArticleId><ArticleId IdType="pubmed">26525923</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuche W, et al. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 2000;11:3419&#x2013;3422. doi: 10.1097/00001756-200011090-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200011090-00003</ArticleId><ArticleId IdType="pubmed">11095490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, et al. MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J. Neurol. Sci. 2010;294:51&#x2013;56. doi: 10.1016/j.jns.2010.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2010.04.005</ArticleId><ArticleId IdType="pubmed">20441996</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelopoulou E, Piperi C. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer&#x2019;s disease. Ann. Transl. Med. 2018;6:255. doi: 10.21037/atm.2018.04.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.04.41</ArticleId><ArticleId IdType="pmc">PMC6046299</ArticleId><ArticleId IdType="pubmed">30069457</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat. Neurosci. 2018;21:329&#x2013;340. doi: 10.1038/s41593-018-0083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0083-7</ArticleId><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, et al. Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD. Stem Cell Rep. 2020;14:892&#x2013;908. doi: 10.1016/j.stemcr.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson KR, et al. Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp. Hematol. 2008;36:1167&#x2013;1175. doi: 10.1016/j.exphem.2008.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exphem.2008.04.009</ArticleId><ArticleId IdType="pmc">PMC2635571</ArticleId><ArticleId IdType="pubmed">18550257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 2019;37:907&#x2013;915. doi: 10.1038/s41587-019-0201-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0201-4</ArticleId><ArticleId IdType="pmc">PMC7605509</ArticleId><ArticleId IdType="pubmed">31375807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923&#x2013;930. doi: 10.1093/bioinformatics/btt656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>